僅限靜脈輸注。不可進行靜脈推注或快速注射。

For intravenous infusion only. Do not administer as an intravenous push or bolus.

0.9% 氯化鈉注射液（生理食鹽水）。

0.9% Sodium Chloride Injection (Normal Saline).

首次輸注：前 30 分鐘應以預定速率之 20% 緩慢開始；若耐受良好，隨後 90 分鐘內以 100% 的預定速率完成輸注。後續輸注：若先前未發生顯著輸注相關反應，可在 60 至 120 分鐘內完成輸注。

Initial infusion: Start slowly at 20% of the target rate for the first 30 minutes; if well-tolerated, complete the remaining infusion at 100% of the rate over the next 90 minutes. Subsequent infusions: If no significant infusion-related reactions occurred previously, complete the infusion over 60 to 120 minutes.

1. 輸注前建議預防性給予止吐劑與抗組織胺藥物。 2. 應嚴密監測輸注相關反應（IRR），最常見為噁心與嘔吐；若發生反應，應依嚴重程度調慢速率、暫停或永久停藥。 3. 本藥物僅適用於經檢測確認為 CLDN18.2 表現陽性之患者。 4. 給藥時需使用 0.2 或 0.22 微米的低蛋白結合線上過濾器。

1. Premedication with antiemetics and antihistamines is recommended prior to infusion. 2. Closely monitor for infusion-related reactions (IRR), with nausea and vomiting being most common; depending on severity, slow, interrupt, or permanently discontinue the infusion if a reaction occurs. 3. Use only in patients confirmed to have CLDN18.2-positive expression. 4. Administer using a 0.2 or 0.22 micron low protein-binding in-line filter.